{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:35:20Z","timestamp":1793975720559,"version":"4.8.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.phrs.2024.107517","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T12:26:04Z","timestamp":1732796764000},"page":"107517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE\u22122 study"],"prefix":"10.1016","volume":"210","author":[{"given":"Cesare","family":"Berra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Manfrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bifari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cipponeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ghelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Centofanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Mortola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lunati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Bucciarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Folli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10397","key":"10.1016\/j.phrs.2024.107517_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.phrs.2024.107517_bib2","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.3390\/jcm12123925","article-title":"Comprehensive cardiovascular and renal protection in patients with type 2 diabetes","volume":"12","author":"Castro Conde","year":"2023","journal-title":"J. Clin. Med"},{"issue":"1","key":"10.1016\/j.phrs.2024.107517_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-021-05585-2","article-title":"Interpreting global trends in type 2 diabetes complications and mortality","volume":"65","author":"Ali","year":"2022","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.phrs.2024.107517_bib4","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.phrs.2024.107517_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"19","key":"10.1016\/j.phrs.2024.107517_bib6","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.phrs.2024.107517_bib7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2337\/db07-1214","article-title":"Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway","volume":"57","author":"Ferdaoussi","year":"2008","journal-title":"Diabetes"},{"issue":"10193","key":"10.1016\/j.phrs.2024.107517_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.phrs.2024.107517_bib9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2337\/dc16-2368","article-title":"Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm","volume":"40","author":"Abdul-Ghani","year":"2017","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.phrs.2024.107517_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93091","article-title":"Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas","volume":"4","author":"Fiorentino","year":"2019","journal-title":"JCI Insight"},{"issue":"24","key":"10.1016\/j.phrs.2024.107517_bib11","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2024.107517_bib12","doi-asserted-by":"crossref","first-page":"E595","DOI":"10.1152\/ajpendo.00236.2023","article-title":"Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets","volume":"325","author":"Folli","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2024.107517_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-diabetic drugs and weight loss in patients with type 2 diabetes","author":"Lazzaroni","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107517_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2840-8-22","article-title":"Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons","volume":"8","author":"Chavez","year":"2009","journal-title":"Cardiovasc Diabetol."},{"issue":"11","key":"10.1016\/j.phrs.2024.107517_bib15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Look","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2024.107517_bib16","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Li","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2024.107517_bib17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardio- vascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2024.107517_bib18","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/dom.14079","article-title":"The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Leiter","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2024.107517_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105052","article-title":"Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists","volume":"160","author":"Berra","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107517_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological propreties of GLP-1 Receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharm. Res"},{"issue":"10","key":"10.1016\/j.phrs.2024.107517_bib21","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"De Fronzo","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2024.107517_bib22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2337\/db07-0790","article-title":"Physiological and molecular determinants of insulin action in the baboon","volume":"57","author":"Chavez","year":"2008","journal-title":"Diabetes"},{"issue":"24","key":"10.1016\/j.phrs.2024.107517_bib23","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107517_bib24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.phrs.2018.09.003","article-title":"Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort","volume":"137","author":"Mirani","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107517_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1099451","article-title":"Real word effectiveness of subcuteneous semaglutide in type 2 diabetes: a retrospective cohort study","volume":"13","author":"Berra","year":"2023","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"6","key":"10.1016\/j.phrs.2024.107517_bib26","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/dom.15020","article-title":"Once-weekly semaglutide use in patients with type 2 diabetes: Real -word data from the SURE Italy observationale study","volume":"25","author":"Napoli","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2024.107517_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104996","article-title":"Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes","volume":"159","author":"Berra","year":"2020","journal-title":"Pharm. Res"},{"issue":"3","key":"10.1016\/j.phrs.2024.107517_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10741-021-10211-9","article-title":"Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes","volume":"28","author":"Gronda","year":"2023","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.phrs.2024.107517_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106374","article-title":"Dapaglifozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study","volume":"183","author":"Lazzaroni","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107517_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106396","article-title":"SGLT2-inhibitors are effective and safe in the elderly: the SOLD study","volume":"183","author":"Lunati","year":"2022","journal-title":"Pharm. Res"},{"issue":"22","key":"10.1016\/j.phrs.2024.107517_bib31","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107517_bib32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the Ominous Octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.phrs.2024.107517_bib33","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/dom.13206","article-title":"Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study","volume":"20","author":"Jabbour","year":"2018","journal-title":"Obes. Metab. Jun."},{"key":"10.1016\/j.phrs.2024.107517_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107040","article-title":"Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide","volume":"199","author":"Lunati","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107517_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC scientific document group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.phrs.2024.107517_bib36","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00592-023-02115-x","article-title":"AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus","volume":"60","author":"Berra","year":"2023","journal-title":"Acta Diabetol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107517_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.phrs.2024.107517_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.phrs.2024.107517_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"beta-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr. Rev."},{"issue":"10","key":"10.1016\/j.phrs.2024.107517_bib40","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.phrs.2024.107517_bib41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3727\/096368911X576027","article-title":"Anti-inflammatory properties of exenatide in human pancreatic islets","volume":"21","author":"Cechin","year":"2012","journal-title":"Cell Transpl."},{"issue":"1","key":"10.1016\/j.phrs.2024.107517_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc Diabetol."},{"issue":"23","key":"10.1016\/j.phrs.2024.107517_bib43","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N. Engl. J. Med"},{"issue":"17","key":"10.1016\/j.phrs.2024.107517_bib44","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.phrs.2024.107517_bib45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jcjd.2020.09.005","article-title":"Practical considerations and rationale for glucagon-like peptide-1receptor agonist plus sodium-dependent glucose cotransporter- 2 inhibitor combination therapy in type 2 diabetes","volume":"45","author":"Goldenberg","year":"2021","journal-title":"Can. J. Diabetes"},{"issue":"10296","key":"10.1016\/j.phrs.2024.107517_bib46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 Inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"33","key":"10.1016\/j.phrs.2024.107517_bib47","doi-asserted-by":"crossref","first-page":"13992","DOI":"10.1073\/pnas.0906471106","article-title":"Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons","volume":"106","author":"Guardado-Mendoza","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2024.107517_bib48","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12933-022-01712-4","article-title":"Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care","volume":"21","author":"Morieri","year":"2022","journal-title":"Cardiovasc Diabetol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107517_bib49","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/dc22-0772","article-title":"Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression","volume":"46","author":"Rodriguez-Valadez","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.phrs.2024.107517_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14697","article-title":"Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: a population-based observational retrospective cohort study","volume":"39","author":"Khunti","year":"2022","journal-title":"Diabet. Med"},{"issue":"4","key":"10.1016\/j.phrs.2024.107517_bib51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/1573403X15666191111123622","article-title":"Assessing cardiovascular risk in patients with diabetes: an update","volume":"16","author":"Damaskos","year":"2020","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.phrs.2024.107517_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154416","article-title":"Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes","volume":"114","author":"Fiorentino","year":"2021","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.phrs.2024.107517_bib53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ajpath.2014.09.009","article-title":"Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates","volume":"185","author":"Fiorentino","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107517_bib54","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.phrs.2024.107517_bib55","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00726-005-0191-z","article-title":"Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects","volume":"28","author":"Paroni","year":"2005","journal-title":"Amino Acids"},{"issue":"2","key":"10.1016\/j.phrs.2024.107517_bib56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000177322","article-title":"Left ventricular function in insulin-dependent and in non-insulin-dependent diabetic patients: radionuclide assessment","volume":"88","author":"Astorri","year":"1997","journal-title":"Cardiology"},{"issue":"3","key":"10.1016\/j.phrs.2024.107517_bib57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11892-007-0028-0","article-title":"ADOPT: lessons from comparison of glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"7","author":"Yki-Jarvinen","year":"2007","journal-title":"Curr. Diab Rep."},{"issue":"9131","key":"10.1016\/j.phrs.2024.107517_bib58","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107517_bib59","article-title":"The efficacy and safety of the combination therapy With GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2024.107517_bib60","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/dom.13380","article-title":"Pancreatic islet of Langerhans' cytoarchitecture and ultrastructure in normal glucose tolerance and in type 2 diabetes mellitus","volume":"20","author":"Folli","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2024.107517_bib61","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s11606-008-0554-8","article-title":"Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification","volume":"23","author":"Schmittdiel","year":"2008","journal-title":"J. Gen. Intern Med"},{"issue":"2","key":"10.1016\/j.phrs.2024.107517_bib62","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2 diabetes","volume":"4","author":"Garc\u00eda-P\u00e9rez","year":"2013","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.phrs.2024.107517_bib63","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13098-020-00559-7","article-title":"Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review","volume":"12","author":"Andreozzi","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.phrs.2024.107517_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/BCI.S36141","article-title":"Protein modifications as manifestations of hyperglycemic glucotoxicity in diabetes and its complications","volume":"9","author":"Zheng","year":"2016","journal-title":"Biochem Insights"},{"issue":"21","key":"10.1016\/j.phrs.2024.107517_bib65","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.phrs.2024.107517_bib66","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.acvd.2020.06.006","article-title":"Myocardial glucotoxicity: mechanisms and potential therapeutic targets","volume":"113","author":"Battault","year":"2020","journal-title":"Arch. Cardiovasc Dis."},{"issue":"8","key":"10.1016\/j.phrs.2024.107517_bib67","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.phrs.2024.107517_bib68","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jacc.2005.05.075","article-title":"Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study","volume":"46","author":"Perseghin","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107517_bib69","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2337\/dc13-1663","article-title":"Islet transplantation stabilizes hemostatic abnormalities and cerebral metabolism in individuals with type 1 diabetes","volume":"37","author":"D'Addio","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.phrs.2024.107517_bib70","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s11255-020-02481-3","article-title":"A unifying model of glucotoxicity in human renal proximal tubular epithelial cells and the effect of the SGLT2 inhibitor dapagliflozin","volume":"52","author":"Eleftheriadis","year":"2020","journal-title":"Urol. Nephrol. Jun."},{"key":"10.1016\/j.phrs.2024.107517_bib71","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.3390\/jcm12237349","article-title":"Pathomechanisms of diabetic kidney disease","volume":"12","author":"Sinha","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2024.107517_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2017.31","article-title":"Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history","volume":"7","author":"Clamp","year":"2017","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.phrs.2024.107517_bib73","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol. 2018"},{"issue":"9","key":"10.1016\/j.phrs.2024.107517_bib74","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the american heart association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824004626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824004626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:49:02Z","timestamp":1734504542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824004626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":74,"alternative-id":["S1043661824004626"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107517","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE\u22122 study","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107517"}}